Physician profile
Brian K DO
NPI 1073807681
$115,823.63
in general payments reported to CMS, 2019-2025
25 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $2,612 · 2021: $22K · 2022: $21K · 2023: $23K · 2024: $22K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $12K · Honoraria: $10K · Food and Beverage: $3,996 · Travel and Lodging: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,200.00 |
| Consulting Fee | $12,196.25 |
| Honoraria | $10,296.25 |
| Food and Beverage | $3,996.19 |
| Travel and Lodging | $2,354.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48,743.74 | 2022-2025 | Ozurdex |
| Allergan, INC. | $19,985.21 | 2019-2021 | |
| Eyepoint US, INC. | $17,104.91 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $7,797.78 | 2025 | Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb Americas INC. | $6,269.44 | 2022-2025 | Surgical Misc, Xipere, Visudyne |
| Alimera Sciences, INC. | $3,960.38 | 2019-2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $2,474.35 | 2022-2025 | Syfovre |
| Genentech, INC. | $1,915.26 | 2021-2025 | Vabysmo, Susvimo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,740.68 | 2019-2021 | |
| Ocular Therapeutix, INC. | $1,600.00 | 2025 | |
| Genentech USA, INC. | $1,575.79 | 2019-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $778.83 | 2019-2025 | Ngenuity |
| Neurotech Pharmaceuticals, INC. | $446.49 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $435.70 | 2023-2025 | Eylea Hd |
| Astellas Pharma US INC | $278.11 | 2023-2025 | Izervay, Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $137.34 | 2025 | |
| Kala Pharmaceuticals, INC. | $124.80 | 2019 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $112.22 | 2019-2021 | |
| Sanofi US Services INC. | $106.28 | 2025 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Oculus Surgical INC. | $17.59 | 2022 | |
| Astellas Pharma Global Development | $17.15 | 2025 | Izervay |
| Penumbra, INC. | $9.06 | 2023 | Ruby Coil |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.